ROCKVILLE, Md., Feb. 2 /PRNewswire-FirstCall/ -- Neuralstem, Inc. announced today that Richard Garr, CEO and President, will present at the 11th Annual BIO CEO & Investor Conference to be held on February 9-10, 2009, at the Waldorf=Astoria Hotel, New York City.
(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO)
Neuralstem’s presentation is scheduled for Monday, February 9, 2009 at 10:00 a.m. Eastern Time.
The presentation will be webcast live and will be available on the Investor Relations section of Neuralstem’s website at www.neuralstem.com. For those who are not available to listen to the live broadcast, the call will be archived.
About Neuralstem
Neuralstem’s patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington’s disease and Amyotrophic Lateral Sclerosis (ALS). The Company filed an IND (Investigational New Drug) application with the FDA for ALS clinical trials in December, 2008, and has entered into a collaborative agreement with Albert-Ludwigs-University, in Freiburg, Germany, to develop clinical trials for Huntington’s disease.
In pre-clinical work, the company’s cells have extended the life of rats with ALS (Lou Gehrig’s disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysis in rats with Ischemic Spastic Paraplegia, as reported in NEUROSCIENCE on June 29, 2007, in collaboration with researchers at University of California San Diego.
CONTACT: Richard Garr, President of Neuralstem, Inc. +1-301-366-4960;
Investors: Ina McGuinness of ICR, Inc., +1-310-954-1100; Media: Deanne
Eagle of Planet Communications, +1-917-837-5866, both for Neuralstem, Inc.
Web site: http://www.neuralstem.com/
